Einstein/Montefiore Department of Medicine

3/5/09: Heart Failure, Beta Blockers, and Adrenergic Receptor Polymorphism

Heart Failure, Beta Blockers, and Adrenergic Receptor Polymorphism

Einstein-Montefiore Department of Medicine Grand Rounds

Thursday, March 5, 2009

8:00 AM
First Floor Lecture Hall, Forchheimer/Einstein

12:15 PM
Cherkasky Auditorium/Montefiore Medical Center


Ronald Zolty, MD
Director, Heart Failure Program
Jack D. Weiler Hospital
Associate Professor of Clinical Medicine, Department of Medicine (Cardiology)
Albert Einstein College of Medicine

Dr. Ronald Zolty is currently Director of the Heart Failure Program at the Weiler Division of Montefiore. His research focuses on pharmacogenetics studies involving beta-blockade therapy in heart failure. It has been known for decades that signaling through the beta 1-adrenergic receptor on the surface of cardiac myocytes augments cardiac contractility acutely. Paradoxically, however, pharmacological blockade of this receptor was found to improve survival in heart failure patients, although the mechanisms are poorly understood. Also, polymorphisms of the gene coding for beta1-adrenergic receptor were shown to influence the responsiveness of individual heart failure patients to beta-blocker drugs. Heart failure patients with the receptor 389G beta1-adrenergic receptor loss of function mutation lose any survival advantage that would be conferred by beta-blockers. Dr. Zolty’s research deepens and extends this era of research to shed light on the basis of this effect and showed that patients with the Receptor 389G loss of function mutation exhibited little improvement in cardiac function from beta-blockers. This research may potentially benefit many patients with heart failure and also exemplifies the power of human genetics to bring about an era of personalized medicine.

Dr. Zolty received the M.D. degree from the University of Geneva Medical School, Switzerland and also earned the Ph.D. degree in Clinical Science from the University of Colorado School of Medicine.


After attending this activity, participants will be able to:

  1. Understand the importance of adreneregic system in heart failure

  2. Understand the importance of beta-blockade therapy in heart failure

  3. Understand the polymorphism role in response to beta-blockade Rx in heart failure


Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Contact Us

Department of Medicine
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
Belfer Building - Room 1008
1300 Morris Park Avenue
Bronx, NY 10461 (directions)

Physicians and Patients:
866-MED-TALK (866-633-8255)

Internal Medicine Residency Program:

Administrative Questions:
Fax: 718-430-8659

Click here to log in